Standard BioTools
LAB
66 hedge funds and large institutions have $89.1M invested in Standard BioTools in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 25 reducing their positions, and 15 closing their positions.
0.57% more ownership
Funds ownership: 58.31% → 58.88% (+0.57%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $89.9M → $89.1M (-$824K)
4% less funds holding
Funds holding: 69 → 66 (-3)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
53% less call options, than puts
Call options by funds: $29K | Put options by funds: $62K
56% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.15M |
| 2 |
CC
Casdin Capital
New York
|
+$2.37M |
| 3 |
Renaissance Technologies
New York
|
+$570K |
| 4 |
SAM
Silverback Asset Management
Chapel Hill,
North Carolina
|
+$98.7K |
| 5 |
MCP
Mirador Capital Partners
Pleasanton,
California
|
+$94.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$2.52M |
| 2 |
NIM
Needham Investment Management
New York
|
-$1.65M |
| 3 |
Millennium Management
New York
|
-$643K |
| 4 |
D.E. Shaw & Co
New York
|
-$467K |
| 5 |
Jane Street
New York
|
-$441K |
LAB Hedge Fund Activity: Q2 2023 in Review
66 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2023, worth a combined $89.1M — down 0.92% from $89.9M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of LAB and 13 opened new positions — a net loss of 2 holders — while 25 trimmed existing stakes and 11 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $4.15M. The largest seller was Primecap Management, cutting an estimated $2.52M.
- 66 institutional investors held Standard BioTools (LAB) as of Q2 2023, down from 69 in Q1 2023.
- Funds reported $89.1M of Standard BioTools stock for Q2 2023, down 0.92% quarter-over-quarter.
- 13 funds opened new Standard BioTools positions in Q2 2023 and 15 closed out, a net change of -2 holders.
- The largest Standard BioTools buyer in Q2 2023 was Balyasny Asset Management, an estimated $4.15M added.
- The largest Standard BioTools seller in Q2 2023 was Primecap Management, an estimated $2.52M sold.
Based on aggregated 13F filings for Q2 2023.